Evidence map›Paper›PMID 31110745›Full record

ArticleClinical case reports2019

Smoldering type adult T-cell leukemia/lymphoma effectively treated with mogamulizumab (anti-CC chemokine receptor 4 monoclonal antibody)-A case report.

Yotaro Nishikawa, Kosuke Mochida, Tamaki Kubo, Nagako Horikawa, Rieko Nemoto, Masahiro Amano

Open access · goldAbstract readCase Reports
PubMed Full text at PMC Publisher
In one paragraph

Article in Clinical case reports, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
0.2field-weighted citation impact, top 49% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 3 citations in OpenAlex.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 1 institution in 1 country.

Yotaro NishikawaDepartment of Dermatology, Faculty of Medicine University of Miyazaki Miyazaki Japan.ORCID https://orcid.org/0000-0002-4796-9711
Kosuke MochidaDepartment of Dermatology, Faculty of Medicine University of Miyazaki Miyazaki Japan.
Tamaki KuboDepartment of Dermatology, Faculty of Medicine University of Miyazaki Miyazaki Japan.
Nagako HorikawaDepartment of Dermatology, Faculty of Medicine University of Miyazaki Miyazaki Japan.
Rieko NemotoDepartment of Dermatology, Faculty of Medicine University of Miyazaki Miyazaki Japan.
Masahiro AmanoDepartment of Dermatology, Faculty of Medicine University of Miyazaki Miyazaki Japan.
University of Miyazaki · JP

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The use of mogamulizumab needs careful consideration because of severe adverse reactions such as graft-vs-host disease. However, refractory specific skin lesions of smoldering type adult T-cell leukemia/lymphoma can be effectively treated with mogamulizumab when patients have no opportunity to receive hematopoietic stem cell transplantation like our case.

Indexed as

adult T-cell leukemia/lymphomaCC chemokine receptor 4graft-vs-host diseasemogamulizumabsmoldering type

Identifiers

PMID31110745
PMCPMC6509667
OpenAlexW2938080715

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.